Inactive Instrument

News Tekmira Pharmaceuticals Corporation Toronto S.E.

Equities

TKM

CA87911B2093

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update	Apr. 18	GL
Arbutus Biopharma : Corporate Presentation - April 2024	Apr. 15	PU
Arbutus Biopharma Obtains Favorable Court Order in Moderna Patent Lawsuit	Apr. 05	MT
Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna	Apr. 04	GL
Moderna Suffers Setback in Lawsuit by Arbutus	Apr. 04	MT
Moderna shares fall after judge sides with Arbutus in patent fight	Apr. 03	RE
Transcript : Arbutus Biopharma Corporation Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 02:05 PM	Mar. 12
Arbutus to Participate in Two Upcoming Investor Conferences	Mar. 08	GL
Arbutus to Participate in Two Upcoming Investor Conferences	Mar. 08	AQ
HC Wainwright Trims Price Target on Arbutus Biopharma to $5 From $6, Keeps Buy Rating	Mar. 01	MT
Arbutus Biopharma Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update	Mar. 01	AQ
Transcript : Arbutus Biopharma Corporation, Q4 2023 Earnings Call, Feb 29, 2024	Feb. 29
Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update	Feb. 29	GL
Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update	Feb. 29	AQ
Arbutus Biopharma Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29	CI
Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update	Feb. 15	GL
Arbutus Announces 2024 Corporate Objectives and Provides Financial Update	Jan. 08	GL
Arbutus Announces 2024 Corporate Objectives and Provides Financial Update	Jan. 08	AQ
Arbutus Biopharma, Inc. Announces Clinical Development Milestones to Advance Its HBV Pipeline	Jan. 08	CI
Arbutus Biopharma Corporation and Barinthus Biotherapeutics plc Present Preliminary Data from Phase 2A Clinical Trial Combining Imdusiran with VTP-300 at AASLD	Nov. 09	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Tekmira Pharmaceuticals Corporation Toronto S.E.

Equities

TKM

CA87911B2093

Summary

Filters